Hub/Healthcare/Use Case 2
#2 of 15Tier 1 — Mission Critical

Medical Imaging AI Inference

AI-powered interpretation of CT, MRI, X-ray, ultrasound, and pathology slides at the point of acquisition. Over 900 FDA-cleared AI/ML algorithms are now deployed across radiology, with vendors including Aidoc, Viz.ai, Annalise.ai, and Siemens AI-Rad Companion operating in production at major health systems — some flagging critical findings in under 30 seconds. OEM scanner manufacturers (GE, Siemens, Philips) are embedding inference natively on-device, intensifying the need for vendor-neutral edge infrastructure. Multimodal foundation models (Med-Gemini, RAD-DINO, Nuance DAX Imaging) are entering clinical validation, requiring substantially more GPU compute than prior single-task CNNs. The medical imaging AI market is projected to reach $25–28B by 2030. FDA's finalized PCCP guidance (September 2025) now allows adaptive AI models to update within pre-authorized boundaries without per-version 510(k) resubmission, fundamentally altering model lifecycle management.

Urgency
10 / 10
Latency
Sub-2 seconds
HIPAA-Sovereign
Yes — PHI must stay on-premises
Maturity
Scaling
$20B
Imaging AI market projected by 2030

Imaging AI market projected by 2030

Overview

AI-powered interpretation of CT, MRI, X-ray, ultrasound, and pathology slides at the point of acquisition. Over 900 FDA-cleared AI/ML algorithms are now deployed across radiology, with vendors including Aidoc, Viz.ai, Annalise.ai, and Siemens AI-Rad Companion operating in production at major health systems — some flagging critical findings in under 30 seconds. OEM scanner manufacturers (GE, Siemens, Philips) are embedding inference natively on-device, intensifying the need for vendor-neutral edge infrastructure. Multimodal foundation models (Med-Gemini, RAD-DINO, Nuance DAX Imaging) are entering clinical validation, requiring substantially more GPU compute than prior single-task CNNs. The medical imaging AI market is projected to reach $25–28B by 2030. FDA's finalized PCCP guidance (September 2025) now allows adaptive AI models to update within pre-authorized boundaries without per-version 510(k) resubmission, fundamentally altering model lifecycle management. Infrastructure implication: On-premises GPU inference (H100/L40S-class or newer) co-located with PACS or directly at the scanner edge. DICOM and increasingly FHIR/DICOMweb integration required. FDA PCCP framework requires predetermined change control plans, continuous monitoring pipelines, and immutable audit trails — replacing rigid per-version 510(k) locks. PHI must remain within the facility or qualified sovereign boundary. Multi-model orchestration needed as sites run 10–30 concurrent AI algorithms across modalities. Why inference, not training: Vision transformer, vision-language foundation model, or CNN runs inference on full imaging studies — often 200–500+ slices per CT. Sub-second per-slice scoring with full-study synthesis and increasingly natural-language radiology co-pilot outputs. Foundation models require 40–80GB VRAM per instance. The model must run at acquisition speed to avoid bottlenecking scanner throughput, and adaptive models must support hot-swappable weight updates under PCCP governance.

Key Context

FDA 510(k) Required
Model version control and audit trails mandated for cleared AI diagnostic tools.
DICOM Integration
Full-study inference across 200–500 CT slices at acquisition speed — no workflow bottleneck.
PACS Co-location
GPU inference co-located with PACS eliminates cloud round-trip and PHI egress risk.

The Penalty Stakes

⚠ Critical Risk: PHI Egress & Regulatory Liability
  • Any cloud transmission of imaging studies violates HIPAA without explicit BAA and technical safeguards
  • FDA-cleared models require version-locked audit trails — cloud APIs break compliance
  • Undetected PE or hemorrhage due to latency or model failure carries direct mortality liability

Business Impact

Validated Performance Benchmarks

Viz.ai: 66 Minutes Faster to Treatment — LVO stroke patients reached treatment 66 minutes faster when Viz.ai AI alert was active — deployed in 1,600+ hospitals. Sub-second PHI-local inference is what makes same-encounter intervention possible. Aidoc PE: 7-Hour Treatment Reduction — 44% increase in PE treatment opportunities; time-to-treatment reduced by 7 hours; length of stay reduced 72 hours — all contingent on real-time inference at the scanner, not batch cloud reads. 1,451 FDA-Cleared AI Devices — 76% of all FDA-authorized AI/ML devices are radiology; 221 cleared in 2023 alone vs. 33 in the entire 1995–2015 period. The market has accelerated beyond infrastructure capacity to deploy — edge inference is the deployment bottleneck.

Industry Programs & Investment

FDA AI/ML Medical Devices Authorized (cumulative): 1,451 total; radiology = 76% (~1,103 devices) (FDA / The Imaging Wire 2025). New Radiology AI Devices Cleared (2023): 221 new devices vs. only 33 in entire 1995–2015 period (JAMA Network Open / PMC Systematic Review 2025). Viz.ai LVO Stroke Time-to-Treatment Reduction: 66 minutes faster; deployed in 1,600+ hospitals (Viz.ai Clinical Outcomes / IntuitionLabs 2024). Aidoc PE Detection Clinical Impact: 44% more treatment opportunities; 7 hrs faster treatment; 72-hr LOS reduction (Aidoc Clinical Outcomes / RSNA 2023–2024). Radiology AI Market (2030 proj.): $760M (2025) → $2.27B (2030), 24.5% CAGR (MarketsandMarkets / PR Newswire 2025).

Infrastructure Requirements

NEXUS OS deploys inside the radiology department, data center, or scanner edge — PHI-contained with zero cloud egress. Supports multi-model orchestration for 10–30+ concurrent FDA-cleared algorithms across modalities on shared GPU infrastructure. NEXUS Foundry fine-tunes foundation models and FDA-cleared base models on your patient population under PCCP-compliant change control, enabling adaptive learning with full audit lineage. Immutable DICOM/FHIR audit trail satisfies FDA PCCP continuous monitoring requirements. Vendor-neutral architecture prevents lock-in to OEM scanner-embedded AI stacks.

PHI-Sovereign InferenceFDA Audit TrailAcquisition-Speed InferencePopulation Fine-TuningPACS IntegrationZero Cloud Dependency
Why Trinidy for Medical Imaging AI Inference
PHI-Sovereign, Acquisition-Speed Inference
  • PHI-Sovereign Inference: NEXUS OS keeps all DICOM data, models, and inference outputs within your facility boundary.
  • FDA Audit Trail: Full model version control and inference logging satisfies 510(k) post-market surveillance requirements.
  • Acquisition-Speed Inference: Co-located GPU delivers sub-2-second full-study reads — no scanner workflow bottleneck.
  • Population Fine-Tuning: NEXUS Foundry improves sensitivity for your specific case mix and patient population.
  • PACS Integration: Direct DICOM integration with your existing PACS — no middleware, no latency, no PHI in transit.
  • Zero Cloud Dependency: No internet required for inference — operational continuity during network outages.